Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

Jen Jie Chieh; K. W. Huang; C. P. Chuang; W. C. Wei; J. J. Dong; Y. Y. Lee

doi:10.1109/TBME.2015.2478845

Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

Jen Jie Chieh^*, K. W. Huang, C. P. Chuang, W. C. Wei, J. J. Dong, Y. Y. Lee

^*Corresponding author for this work

Undergraduate Program of Electro-Optical Engineering

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe₃O₄) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

Original language	English
Article number	7273866
Pages (from-to)	1681-1686
Number of pages	6
Journal	IEEE Transactions on Biomedical Engineering
Volume	63
Issue number	8
DOIs	https://doi.org/10.1109/TBME.2015.2478845
Publication status	Published - 2016 Aug

Keywords

Des-gamma-carboxy prothrombin
enzyme-linked
hepatocellular carcinoma
immunomagnetic reduction
immunosorbent assay

ASJC Scopus subject areas

Biomedical Engineering

Access to Document

10.1109/TBME.2015.2478845

Cite this

@article{ad64277899fc402cb2d7402a814f588b,

title = "Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma",

abstract = "The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.",

keywords = "Des-gamma-carboxy prothrombin, enzyme-linked, hepatocellular carcinoma, immunomagnetic reduction, immunosorbent assay",

author = "Chieh, {Jen Jie} and Huang, {K. W.} and Chuang, {C. P.} and Wei, {W. C.} and Dong, {J. J.} and Lee, {Y. Y.}",

note = "Publisher Copyright: {\textcopyright} 1964-2012 IEEE.",

year = "2016",

month = aug,

doi = "10.1109/TBME.2015.2478845",

language = "English",

volume = "63",

pages = "1681--1686",

journal = "IEEE Transactions on Biomedical Engineering",

issn = "0018-9294",

publisher = "IEEE Computer Society",

number = "8",

}

TY - JOUR

T1 - Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

AU - Chieh, Jen Jie

AU - Huang, K. W.

AU - Chuang, C. P.

AU - Wei, W. C.

AU - Dong, J. J.

AU - Lee, Y. Y.

PY - 2016/8

Y1 - 2016/8

N2 - The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

AB - The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

KW - Des-gamma-carboxy prothrombin

KW - enzyme-linked

KW - hepatocellular carcinoma

KW - immunomagnetic reduction

KW - immunosorbent assay

UR - http://www.scopus.com/inward/record.url?scp=84986270047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986270047&partnerID=8YFLogxK

U2 - 10.1109/TBME.2015.2478845

DO - 10.1109/TBME.2015.2478845

M3 - Article

C2 - 26415145

AN - SCOPUS:84986270047

SN - 0018-9294

VL - 63

SP - 1681

EP - 1686

JO - IEEE Transactions on Biomedical Engineering

JF - IEEE Transactions on Biomedical Engineering

IS - 8

M1 - 7273866

ER -

Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this